Herpes zoster prophylaxis: Essential for treating newly diagnosed multiple myeloma patients

Wen-Ying Lin1, Chun-Kuang Tsai2,3, Chiu-Mei Yeh2,4

  • 1Department of Medicine, Taipei Veterans General Hospital, Taipei, Taiwan.

Cancer Medicine
|September 21, 2022
PubMed
Abstract

Insights

Multiple myeloma patients are vulnerable to herpes zoster (HZ) infections. Continuing HZ prophylaxis during cancer treatment is crucial, especially for those undergoing stem cell transplant (SCT).

Area of Science:

  • Oncology
  • Infectious Diseases
  • Pharmacology

Background:

  • Multiple myeloma (MM) compromises immune function, increasing susceptibility to opportunistic infections like herpes zoster (HZ).
  • HZ infection significantly impacts patient quality of life and healthcare costs.
  • Identifying HZ risk factors and optimizing prophylaxis strategies in MM patients is essential.

Purpose of the Study:

  • To identify risk factors for HZ infection in multiple myeloma patients.
  • To evaluate the effectiveness of anti-HZ prophylaxis drugs regarding dosage, type, and duration.
  • To inform clinical practice for HZ prevention in MM patients.

Main Methods:

  • Retrospective analysis of 551 MM patients at Taipei Veterans General Hospital (2009-2021).
  • Data collection included patient characteristics and HZ infection incidence.
  • Multivariate analysis assessed risk factors including age, renal function, SCT, and prophylaxis status.

Main Results:

  • Non-prophylaxis, autologous SCT, and allogeneic SCT were associated with significantly higher HZ infection risk.
  • Different dosages and types of anti-HZ drugs demonstrated comparable protective effects.
  • Discontinuing prophylaxis before active cancer treatment increased HZ risk (aHR 3.09).

Conclusions:

  • MM patients require HZ prophylaxis throughout active cancer-related treatment.
  • Stem cell transplant (SCT) recipients remain at high risk for HZ infection, even with prophylaxis.
  • Continued vigilance and adherence to prophylaxis are recommended for high-risk MM patients.

Related Concept Videos

Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists01:27

Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists

5-HT3 receptor antagonists, such as dolasetron, granisetron (Kytril), ondansetron (Zofran), and palonosetron (Axoli), are crucial in managing chemotherapy-induced nausea and vomiting (CINV) and postoperative nausea. These drugs selectively block 5-HT3 receptors in the visceral vagal and spinal afferent nerves, chemoreceptor trigger zone, and the vomiting center. They have a rapid onset of action and can be given as a single dose before chemotherapy. Ondansetron and granisetron, in particular,...
307
Myasthenia Gravis: Overview and Treatment01:20

Myasthenia Gravis: Overview and Treatment

Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
1.8K
Chemotherapy-Induced Nausea and Vomiting: Dopamine Receptor Antagonists01:29

Chemotherapy-Induced Nausea and Vomiting: Dopamine Receptor Antagonists

Dopamine receptor antagonists, also known as antipsychotic agents, are critical in managing chemotherapy-induced vomiting. These antiemetic agents block dopamine receptors in the chemoreceptor trigger zone (CTZ), inhibiting signal transmission to the vomiting center. Antipsychotic agents encompass phenothiazines (PTZ), butyrophenones, benzamides, and thienobenzodiazepines (Zyprexa), which are utilized for their antiemetic and sedative properties.
Phenothiazines, such as prochlorperazine...
422
Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists01:28

Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists

Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy.  SP binds and activates...
250
Myocarditis IV: Nursing Management01:22

Myocarditis IV: Nursing Management

Myocarditis is an inflammatory condition of the myocardium requiring meticulous nursing management for optimal patient outcomes. Effective management begins with a thorough assessment of the patient's medical history, paying close attention to past infections, autoimmune disorders, travel history, and exposure to toxins or drugs. Recent viral infections and systemic diseases are particularly relevant due to their potential role in triggering myocarditis.Physical Examination and MonitoringThe...
17
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.4K